StockNews.AI
BNTX
StockNews.AI
119 days

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

1. BioNTech will announce Q1 2025 financial results on May 5, 2025. 2. A conference call will discuss results and corporate updates. 3. BioNTech is focused on innovative cancer therapies and mRNA vaccines. 4. They collaborate with major pharmaceutical companies for diverse drug development. 5. Webcast and presentation materials will be accessible post-call.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results announcements can positively affect stock prices. Historical trends show price increases post-earnings announcements if results exceed expectations.

How important is it?

The article provides critical information on an upcoming earnings report, likely influencing investor decisions and stock performance.

Why Short Term?

Immediate impact expected around the earnings announcement. Previous earnings calls have influenced stock price within days.

Related Companies

PFERHHBYGILDREGN
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link. Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call. About BioNTechBiopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancers includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron. For more information, please visit www.BioNTech.com. CONTACTS Investor RelationsMichael HorowiczInvestors@biontech.de Media Relations Jasmina Alatovic Media@biontech.de

Related News